Advertisement

Everolimus in advanced solid tumors: when to start, early or late

Abstract

Everolimus is an oral derivative of rapamycin which acts as a signal transduction inhibitor. It targets the mammalian target of rapamycin (mTOR), a key serine/threonine kinase regulating cell growth and angiogenesis. Everolimus has been approved for the treatment of pancreatic neuroendocrine tumors (pNETs), metastatic renal cell carcinoma (mRCC), and breast carcinoma. The activity of everolimus was demonstrated in three phase III randomized placebo-controlled trials, RADIANT-3, RECORD 1 and BOLERO 2, in patients with pNETs, mRCC and breast carcinoma, respectively. All three trials reported a statistically significant increase in median progression-free survival, the primary endpoint of the studies, in favor of everolimus. The absence of an overall survival benefit could be related to the cross-over design and subsequent therapies. The focus of our paper is on the best timing to start treatment with everolimus, while additional questions concern the opportuneness of intermittent use of everolimus specifically in long-responding patients. Lastly, we suggest this treatment could be optimized on the basis of patient and disease characteristics.

Tumori 2014; 100(1): e2 - e3

Article Type: COMMENTARY

DOI:10.1700/1430.15827

Authors

Sara Pusceddu, Anna Tessari, Isabella Testa, Giuseppe Procopio

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Pusceddu, Sara [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Tessari, Anna [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Testa, Isabella [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Procopio, Giuseppe [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.